secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001367644-24-000093
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions approves 2.1M share increase to stock plan; reports NARCAN OTC launch, DoD contracts
--------------------------------------------------------------------------------

- Stockholders approved 2.1M share increase to stock incentive plan; full-value awards now count one-for-one.
- Elected directors DeGolyer, Fowler, White; say-on-pay passed; EY ratified as auditor.
- Launched OTC NARCAN Nasal Spray; FDA approved two-dose anthrax vaccine CYFENDUS.
- Won $379.6M DoD contract for RSDL kits and $235.8M contract for BioThrax.
- Cut ~$240M annualized OpEx; extended secured credit facility to May 2025; divested Travel Health up to $380M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000093/0001367644-24-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000093/ebs-20240523.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer